ICER will conduct a new analysis it plans to release on an annual basis titled the “Launch Price and Access Report” which will examine launch pricing for FDA-approved treatments. This report will review the affordability and access of the treatments and their value to the overall health system.

ICER will examine all novel drug approvals in the previous 2 years and will:

  1. Analyze list and net price trends
  2. Conduct an in-depth review of drugs that were subject to an ICER analysis
  3. Analyze affordability and access concerns, such as trends in patient out-of-pocket costs.

    Dates are tentative — to be finalized as report development continues.

For more information please contact Kelsey Gosselin, Program Director, at kgosselin@icer.org.